Status:
UNKNOWN
Weekly Plasma EBV DNA for Non-metastatic Nasopharyngeal Carcinoma
Lead Sponsor:
The University of Hong Kong
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
Brief Summary
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV). Radiation therapy alone is ...
Detailed Description
Patients with histologically confirmed previously untreated NPC are be recruited to join tis study. The study has obtained approval from local institutional review board. After written informed conse...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed previously untreated nasopharyngeal carcinoma
Exclusion
- Patients who are pregnant or lactating
- Patients who are not mentally capable of giving written informed consent
- Patients with performance status ECOG=3 or above or patients who are expected not able to tolerate radiation therapy and/or chemotherapy
- Patients who refuse active treatment for their nasopharyngeal carcinoma
- Patients who cannot comply with radiation therapy and/or chemotherapy for their nasopharyngeal carcinoma
Key Trial Info
Start Date :
February 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03830996
Start Date
February 1 2016
End Date
December 1 2020
Last Update
October 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Oncology, Queen Mary Hospital
Hong Kong, Hong Kong